{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:11:54Z","timestamp":1761894714543},"reference-count":30,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,5,14]],"date-time":"2008-05-14T00:00:00Z","timestamp":1210723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2008,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> In patients with multiple endocrine neoplasia type 1 (MEN1), expression of somatostatin receptor (SST) in parathyroid adenomas and effectiveness of therapy with somatostatin analogues on primary hyperparathyroidism (PHP) have been scarcely investigated.<\/jats:p><jats:p><jats:bold>Objective\u2002<\/jats:bold> To evaluate the effects of depot long acting octreotide (OCT\u2010LAR) in patients with MEN1\u2010related PHP.<\/jats:p><jats:p><jats:bold>Patients\u2002<\/jats:bold> Eight patients with a genetically confirmed MEN1, presenting both PHP and duodeno\u2010pancreatic neuroendocrine tumours (NET), were enrolled.<\/jats:p><jats:p><jats:bold>Design\u2002<\/jats:bold> The initial treatment was OCT\u2010LAR 30\u00a0mg every 4\u00a0weeks. This therapy was established to stabilize the duodeno\u2010pancreatic NET before to perform parathyroidectomy for PHP. Before OCT\u2010LAR therapy, a SST scintigraphy was performed in all patients. SST subtype 2A immunohistochemistry was performed on parathyroid tumour samples from three patients undergone parathyroidectomy after OCT\u2010LAR therapy.<\/jats:p><jats:p><jats:bold>Measurements\u2002<\/jats:bold> Serum concentrations of PTH, calcium and phosphorus as well as the 24\u2010h urine calcium\u00a0:\u00a0 creatinine ratio and the renal threshold phosphate concentration were evaluated before and after OCT\u2010LAR.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> After OCT\u2010LAR therapy, hypercalcaemia and hypercalciuria normalized in 75% and 62\u00b75% of patients, respectively, and serum phosphorus and renal threshold phosphate significantly increased. Serum PTH concentrations significantly decreased in all patients and normalized in two of them. SST subtype 2A immunostaining was found in all parathyroid adenomas investigated, while SST scintigraphy showed a positive parathyroid tumour uptake in three of eight patients (37\u00b75%).<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Six months of OCT\u2010LAR therapy controlled hypercalcaemia and hypercalciuria in two\u2010thirds of patients with MEN1\u2010related PHP. Direct OCT\u2010LAR effects mediated by binding to SST expression on parathyroid tumour cells are likely the main mechanism to explain the activity of this compound on calcium and phosphorus abnormalities in MEN1 PHP.<\/jats:p>","DOI":"10.1111\/j.1365-2265.2008.03301.x","type":"journal-article","created":{"date-parts":[[2008,5,14]],"date-time":"2008-05-14T11:40:25Z","timestamp":1210765225000},"page":"756-762","source":"Crossref","is-referenced-by-count":26,"title":["Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients"],"prefix":"10.1111","volume":"69","author":[{"given":"Antongiulio","family":"Faggiano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidice Brandao","family":"Tavares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Libuse","family":"Tauchmanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Milone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gelsomina","family":"Mansueto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Ramundo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Laura","family":"Del Basso De Caro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaetano","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annamaria","family":"Colao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,10,14]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-8-4-391"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-129-6-199809150-00011"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(87)90008-8"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021597"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0842"},{"key":"e_1_2_5_7_2","first-page":"222","article-title":"Somatostatin receptors: clinical implications for endocrinology and oncology","volume":"190","author":"Lamberts S.W.","year":"1995","journal-title":"Ciba Foundation Symposium"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh216"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19991115)86:10<2154::AID-CNCR39>3.0.CO;2-W"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2003.01164.x"},{"key":"e_1_2_5_11_2","first-page":"227","article-title":"Hypercalcemia due to hyperparathyroidism treated with a somatostatin analogue","volume":"145","author":"Miller D.","year":"1991","journal-title":"Canadian Medical Association Journal"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800810819"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6060(97)90047-7"},{"key":"e_1_2_5_14_2","first-page":"1078","article-title":"[Octreotide therapy in multiple endocrine neoplasia type\u20101]","volume":"143","author":"Valkusz Z.","year":"2002","journal-title":"Orvosi Hetilap"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0260"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(75)92736-1"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1159\/000201202"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800954"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1995.tb00934.x"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/110241501750099294"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6060(03)00406-9"},{"key":"e_1_2_5_22_2","first-page":"13","article-title":"Introduction to a revised clinicopathological classification of neuroendocrine tumors of the gastroenteropancreatic tract","volume":"44","author":"Rindi G.","year":"2000","journal-title":"Quarterly Journal of Nuclear Medicine"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1006\/frne.1999.0183"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1159\/000079048"},{"key":"e_1_2_5_25_2","volume-title":"In World Health Organization International Histological Classification of Tumours.","author":"Solcia E.","year":"2000"},{"key":"e_1_2_5_26_2","first-page":"406","article-title":"[Effects of octreotide on serum and urine electrolytes in a patient with parathyroid carcinoma: clinical case]","volume":"21","author":"Ybarra J.","year":"2001","journal-title":"Nefrologia"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990101)85:1<188::AID-CNCR26>3.0.CO;2-3"},{"key":"e_1_2_5_28_2","first-page":"1078","article-title":"Vasoactive intestinal polypeptide\u2010, neurotensin\u2010, substance P\u2010, gastrin\u2010releasing peptide\u2010, calcitonin\u2010, calcitonin gene related peptide\u2010, and somatostatin\u2010like immunoreactivities in human parathyroid glands","volume":"110","author":"Weber C.J.","year":"1991","journal-title":"Surgery"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.51.517"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1009961116472"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002239900303"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2008.03301.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.2008.03301.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T20:56:56Z","timestamp":1697230616000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.2008.03301.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,14]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["10.1111\/j.1365-2265.2008.03301.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2008.03301.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,14]]}}}